Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q4 FY21 results · Jan–Mar 2021
Natco Pharma reported revenue from operations of ₹331.30 crore (down 27.2% from Q4 FY20) and net profit of ₹53.00 crore (down 43.1% from Q4 FY20) for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 331.30 | 454.80 | −27.2% | 355.20 | −6.7% |
| Other income | 28.40 | 22.40 | +26.8% | 30.80 | −7.8% |
| Total income | 359.70 | 477.20 | −24.6% | 386.00 | −6.8% |
| Profit before tax | 70.70 | 116.70 | −39.4% | 80.10 | −11.7% |
| Net profit for the period | 53.00 | 93.20 | −43.1% | 63.40 | −16.4% |
| EPS, basic (₹) | 2.91 | 5.17 | −43.7% | 3.44 | −15.4% |
| Net margin (%) | 16.0 | 20.5 | 17.8 |
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 311.50 | 420.10 | −25.9% | 330.90 | −5.9% |
| Other income | 29.10 | 38.60 | −24.6% | 24.90 | +16.9% |
| Total income | 340.60 | 458.70 | −25.7% | 355.80 | −4.3% |
| Profit before tax | 73.40 | 123.90 | −40.8% | 70.70 | +3.8% |
| Net profit for the period | 57.20 | 101.00 | −43.4% | 54.70 | +4.6% |
| EPS, basic (₹) | 3.14 | 5.55 | −43.4% | 3.00 | +4.7% |
| Net margin (%) | 18.4 | 24.0 | 16.5 |
Consolidated
- Filed with BSE
- 17 Jun 2021, 19:17 IST
- Board meeting
- 17 Jun 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 17 Jun 2021, 19:17 IST
- Board meeting
- 17 Jun 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE